Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have earned a consensus rating of “Hold” from the thirty-one research firms that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $449.95.
A number of equities research analysts have commented on REGN shares. Canaccord Genuity reissued a “buy” rating and issued a $522.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 7th. JPMorgan Chase & Co. raised their target price on Regeneron Pharmaceuticals from $455.00 to $457.00 and gave the company a “neutral” rating in a report on Wednesday, January 24th. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 5th. Guggenheim set a $530.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 9th. Finally, Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th.
In related news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $340.00, for a total value of $680,000.00. Following the sale, the director now owns 14,000 shares of the company’s stock, valued at approximately $4,760,000. The disclosure for this sale can be found here. Company insiders own 10.80% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. ADAMCAPITAL Gestao de Recursos Ltda. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $29,252,000. Cambridge Investment Research Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 2.8% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 9,302 shares of the biopharmaceutical company’s stock worth $3,497,000 after buying an additional 256 shares during the last quarter. KCM Investment Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 34.7% in the 4th quarter. KCM Investment Advisors LLC now owns 936 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 241 shares during the last quarter. Xact Kapitalforvaltning AB boosted its stake in Regeneron Pharmaceuticals by 23.6% in the 4th quarter. Xact Kapitalforvaltning AB now owns 17,772 shares of the biopharmaceutical company’s stock worth $6,682,000 after buying an additional 3,397 shares during the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in Regeneron Pharmaceuticals by 16.1% in the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 65,862 shares of the biopharmaceutical company’s stock worth $24,761,000 after buying an additional 9,157 shares during the last quarter. Hedge funds and other institutional investors own 66.40% of the company’s stock.
Regeneron Pharmaceuticals (REGN) traded down $5.56 during trading on Friday, reaching $335.86. The company’s stock had a trading volume of 291,405 shares, compared to its average volume of 984,565. Regeneron Pharmaceuticals has a 12 month low of $313.53 and a 12 month high of $543.55. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $36,374.32, a P/E ratio of 33.07, a P/E/G ratio of 1.06 and a beta of 1.54.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter last year, the company earned $3.04 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 28.9% compared to the same quarter last year. equities analysts anticipate that Regeneron Pharmaceuticals will post 19.2 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals Inc (REGN) Receives Average Recommendation of “Hold” from Analysts” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/regeneron-pharmaceuticals-inc-regn-receives-average-recommendation-of-hold-from-analysts.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.